glp 1 mechanism of action incretin The mechanisms dual receptor agonists. Glucagon-like GLP-1: Actions on Beta-cell Mass

Longer half-life means more drug overlap when you inject early

Gastric emptying delay GLP-1 agonists slow the rate at which food leaves the stomach, promoting satiety and reducing post-meal glucose spikes

Expansion of coverage under Medicare of GLP-1s to treat obesity under the BALANCE model is likely to increase utilization above current levels, as Medicare begins to meet the demand for obesity drugs among beneficiaries who have been unable to access or afford these medications to date

The relationship between timing and side effects is not definitively established in clinical trials, as most studies do not systematically compare morning versus evening administration

A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans